BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 30993909)

  • 21. Prognostic significance of molecular characteristics of cerebrospinal fluid for non-small cell lung cancer patients with leptomeningeal metastasis.
    Li N; Liu Y; Duan J; Yang B; Bai H; Sun R; Yu L; Wang J
    Thorac Cancer; 2019 Aug; 10(8):1673-1682. PubMed ID: 31368671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer.
    Xu Q; Chen X; Qian D; Wang Y; Meng S; Liu H; Zhou C
    Thorac Cancer; 2015 Jul; 6(4):407-12. PubMed ID: 26273394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
    Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
    Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of EGFR/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy.
    Oyoshi H; Hirata H; Hirano Y; Zenda S; Zhou Y; Tomizawa K; Fujisawa T; Nakamura M; Hojo H; Motegi A; Kageyama SI; Zenke Y; Goto K; Ishihara S; Naganawa S; Akimoto T
    Clin Exp Metastasis; 2023 Oct; 40(5):407-413. PubMed ID: 37468822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognostic Analysis of Patients with Advanced Non-small Cell Lung Cancer 
in Different Genotypes].
    Liu P; Wu Y; Zhou L; Qin N; Zhang Q; Zhang H; Li X; Zhang X; Lv J; Yang X; Wang J; Zhang S
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):741-750. PubMed ID: 29167003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Outcomes of Patients with Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis in the Modern Target Therapy Era.
    Wang Y; Li J; Liu T; Ge M; Ji X; Chu Z; Zhan Q; Liang X; Zhou X
    World Neurosurg; 2023 Feb; 170():e500-e509. PubMed ID: 36396052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
    Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
    Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.
    Liao BC; Lee JH; Lin CC; Chen YF; Chang CH; Ho CC; Shih JY; Yu CJ; Yang JC
    J Thorac Oncol; 2015 Dec; 10(12):1754-61. PubMed ID: 26334749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated 
Non-small Cell Lung Cancer and Brain Metastases].
    Liu G; Zhang X; Tian C; Xia G; Liu P; Zhang Q; Li X; Zhang H; Qin N; Wang J; Zhang S
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):501-7. PubMed ID: 27561798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.
    Yi Y; Cai J; Xu P; Xiong L; Lu Z; Zeng Z; Liu A
    J Transl Med; 2022 Mar; 20(1):122. PubMed ID: 35287683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs.
    Yang L; Hao X; Hu X; Wang Z; Yang K; Mi Y; Yang Y; Xu H; Yang G; Wang Y
    Thorac Cancer; 2020 Dec; 11(12):3501-3509. PubMed ID: 33075201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
    Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
    Yin K; Li YS; Zheng MM; Jiang BY; Li WF; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Yang XN; Chen HJ; Yan HH; Li LL; Wu YL; Zhang XC
    Lung Cancer; 2019 May; 131():134-138. PubMed ID: 31027690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers.
    Nakagawa K; Takano K; Nishino K; Ohe S; Nakayama T; Arita H
    J Neurooncol; 2024 May; 167(3):397-406. PubMed ID: 38430420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
    Gui Q; Liu J; Li D; Xu C
    World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
    Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study.
    Mitsuya K; Nakasu Y; Hayashi N; Deguchi S; Takahashi T; Murakami H; Naito T; Kenmotsu H; Ono A; Wakuda K; Harada H
    PLoS One; 2019; 14(1):e0210074. PubMed ID: 30629621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.